Realizing the full potential of clinicogenomics
Length: 50 minutes
Paving the way for new health discoveries
Hailed as the next frontier in drug discovery and development, genomics has, in many ways, fallen short. One reason is the lack of existing datasets combining high-quality genomic sequencing information and rich, longitudinal phenotypic information.
During this Endpoints News webinar, industry experts discuss the progress made in clinicogenomics, the development of these datasets and their application in health care, drug discovery and development.
FEATURED SPEAKERS:
Dr. Ashley Brenton, VP, Real-World Evidence and Genomics, Life Sciences, Optum
Dr. Michael Hultner, VP, Head of Genomics Strategy, Optum Arsalan Arif, Founder and Publisher, Endpoints News (moderator)
Related resources
Clinicogenomics: The next big leap in real-world data
Optum clinical genomics is positioned to shape a new generation of evidence that accelerates understanding of disease.
Clinicogenomics: new, linked data is advancing research
Rich, longitudinal clinicogenomics data can fuel all stages of drug development.
